AU2020304001B2 - Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them - Google Patents

Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Info

Publication number
AU2020304001B2
AU2020304001B2 AU2020304001A AU2020304001A AU2020304001B2 AU 2020304001 B2 AU2020304001 B2 AU 2020304001B2 AU 2020304001 A AU2020304001 A AU 2020304001A AU 2020304001 A AU2020304001 A AU 2020304001A AU 2020304001 B2 AU2020304001 B2 AU 2020304001B2
Authority
AU
Australia
Prior art keywords
crystalline form
compound
peaks
solid crystalline
chosen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020304001A
Other languages
English (en)
Other versions
AU2020304001A1 (en
Inventor
Danny T. DING
Shaoxin FENG
William R. Perrault
Xiaoda YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naurex Inc
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of AU2020304001A1 publication Critical patent/AU2020304001A1/en
Application granted granted Critical
Publication of AU2020304001B2 publication Critical patent/AU2020304001B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020304001A 2019-06-24 2020-06-23 Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them Active AU2020304001B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865826P 2019-06-24 2019-06-24
US62/865,826 2019-06-24
PCT/US2020/039163 WO2020263847A1 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (s)-2-((2s,3r) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Publications (2)

Publication Number Publication Date
AU2020304001A1 AU2020304001A1 (en) 2022-01-27
AU2020304001B2 true AU2020304001B2 (en) 2026-04-09

Family

ID=74060350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020304001A Active AU2020304001B2 (en) 2019-06-24 2020-06-23 Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them

Country Status (11)

Country Link
US (1) US20220267341A1 (enExample)
EP (1) EP3986399A4 (enExample)
JP (2) JP7617043B2 (enExample)
CN (1) CN114364380A (enExample)
AU (1) AU2020304001B2 (enExample)
BR (1) BR112021026380A2 (enExample)
CA (1) CA3144600A1 (enExample)
IL (1) IL289198A (enExample)
MA (1) MA56550A (enExample)
MX (2) MX2022000069A (enExample)
WO (1) WO2020263847A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4484431A3 (en) * 2019-06-24 2025-03-26 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120786A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9512134B2 (en) * 2013-01-29 2016-12-06 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2017201283A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
ES2416354T3 (es) * 2005-06-21 2013-07-31 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina, método de producción del mismo y uso del mismo
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
DK3436463T3 (da) * 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
EP4484431A3 (en) * 2019-06-24 2025-03-26 Naurex Inc. Processes and intermediates for producing diazaspiro lactam compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014120786A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
US9512134B2 (en) * 2013-01-29 2016-12-06 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2017201283A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Also Published As

Publication number Publication date
WO2020263847A1 (en) 2020-12-30
JP2025069143A (ja) 2025-04-30
MX2022000069A (es) 2022-05-24
MA56550A (fr) 2022-04-27
US20220267341A1 (en) 2022-08-25
KR20220061088A (ko) 2022-05-12
CA3144600A1 (en) 2020-12-30
EP3986399A4 (en) 2023-06-07
JP7617043B2 (ja) 2025-01-17
JP2022539342A (ja) 2022-09-08
IL289198A (en) 2022-02-01
AU2020304001A1 (en) 2022-01-27
CN114364380A (zh) 2022-04-15
MX2025002579A (es) 2025-04-02
BR112021026380A2 (pt) 2022-05-10
EP3986399A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
EP3889147A1 (en) 4-({(2s)-2-[4-{5-chloro-2-[4-(trifluoromethyl)-1h-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2h)-yl]butanoyl}-amino)-2-fluorobenzamide acetone and its use
KR102162208B1 (ko) 7-((3s,4s)-3-[(사이클로프로필아미노)메틸]-4-플루오로피롤리딘-1-일)-6-플루오로-1-(2-플루오로에틸)-8-메톡시-4-옥소-1,4-다이하이드로퀴놀린-3-카복실산 결정
JP6471103B2 (ja) ヒスタミンｈ４受容体のベンゾイミダゾール−２−イルピリミジンモジュレータ
EP2791141B1 (en) Tofacitinib mono-tartrate salt
EP2985277A1 (en) Dipyrromethene crystal and method for manufacturing same
CA2768553C (en) Anhydrate of tiotropium bromide
JP5635181B2 (ja) ニトロイミダゾール系化合物、その製造方法および用途
KR20100103427A (ko) 아연 분말을 이용한 메로페넴의 개선된 제조방법
US11584715B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
AU2020304001B2 (en) Solid forms of tert-butyl (S)-2-((2S,3R) -1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them
AU2020210998A1 (en) Crystal form of 1,2,3-triazolo(1,5-a)pyrazines derivative and preparation method for crystal form
KR102768447B1 (ko) (-)-시벤졸린 숙신산염의 신규한 제조 공정
KR102958083B1 (ko) 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
KR20260061467A (ko) 고체 형태의 tert-부틸 (S)-2-((2S,3R)-1-아미노-3-히드록시-1-옥소부탄-2-일)-1-옥소-2,5-디아자스피로[3.4]옥탄-5-카르복실레이트 및 제조 방법
US20120220655A1 (en) Crystalline forms of fesoterodine fumarate and fesoterodine base
EA044016B1 (ru) Твердые формы трет-бутил(s)-2-((2s,3r)-1-амино-3-гидрокси-1-оксобутан-2-ил)-1-оксо-2,5-диазаспиро[3.4]октан-5-карбоксилата и способы их получения
HK40068368B (zh) 索吡溴铵的晶型及其制备方法
WO2025029842A2 (en) Process of making 2-[(3r)-2-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4- methyl-4[4-(oxetan-3-yl)piperazin-l-yl]-pent-2-enenitrile and solvate forms thereof
CN118475589A (zh) 一种神经激肽-1拮抗剂前药化合物的晶型
HK40068368A (en) Crystalline form of sofpironium bromide and preparation method thereof
US8569289B2 (en) Fumarate salt of 4-bromophenyl 1,4-diazabicyclo[3.2.2]nonane-4-carboxylate, crystalline forms thereof, preparation thereof and therapeutic use thereof
HK1218544B (en) Salt of omecamtiv mecarbil and process for preparing salt
JP2012500192A (ja) １−イソプロピル−４−｛［４−（テトラヒドロ−２ｈ−ピラン−４−イルオキシ）フェニル］カルボニル｝ヘキサヒドロ−１ｈ−１，４−ジアゼピンの塩およびその調製方法